Cambridge healthtech institutes inaugural bispecific antibodies for cancer immunotherapy engineering next generation biotherapeutics in immuno oncology. Cambridge healthtech institutes sixth annual advancing bispecific antibodies and combination therapy to the clinic creating the killer combo may 2 3 2018 world . Bispecific antibody pipeline congress will unite all the key opinion leaders including regulators clinicians and industry experts to deepen our understanding of . Cd47 serves as an anti phagocytic receptor that is upregulated by cancer to promote immune escape as such cd47 is the focus of intense immuno oncology . Xencor announces strategic collaboration with novartis for bispecific programs including xmab 14045 and xmab 13676